

Christine Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5455636/publications.pdf>

Version: 2024-02-01

11
papers

219
citations

1684188

5
h-index

1872680

6
g-index

12
all docs

12
docs citations

12
times ranked

448
citing authors

#	ARTICLE	IF	CITATIONS
1	The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies. <i>Cancer Letters</i> , 2021, 503, 11-18.	7.2	47
2	Abstract PO-067: The transactivation domain of TWIST1 is required for TWIST1-induced aggressiveness in non-small cell lung cancer. , 2021, , .		0
3	Abstract PO-030: The harmala alkaloid harmine as a novel cancer cell radiosensitizer. , 2021, , .		0
4	Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1931.	12.8	38
5	Abstract 3926: Establishment of patient-derived organoids as a tool to characterize the molecular mechanisms of SCLC chemo-radiation resistance. , 2020, , .		0
6	Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations. <i>Advances in Cancer Research</i> , 2019, 142, 23-62.	5.0	12
7	Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. <i>Haematologica</i> , 2018, 103, 1218-1228.	3.5	30
8	Novel Allosteric Inhibitors of Heat Shock Protein 70 As Agents to Probe Protein Homeostasis and Overcome Proteasome Inhibitor Resistance in Multiple Myeloma. <i>Blood</i> , 2018, 132, 3212-3212.	1.4	1
9	The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2375-2386.	4.1	90
10	Hijacking Myeloma Metabolism to Target Cytotoxic Chemotherapy to Malignant Plasma Cells With Decreased Bone Marrow Toxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e53.	0.4	0
11	Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Through Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma. <i>Blood</i> , 2016, 128, 2098-2098.	1.4	0